NYSE · LLY
Eli Lilly and Company
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
Loading market information…
NASDAQ · CYCC · USD
Stock price, earnings
Quote as of Sep 11, 2025, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Cyclacel Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.93% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Cyclacel Pharmaceuticals, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Cyclacel Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the clinical development stage, focused on discovering and advancing treatments for various cancers and other diseases involving abnormal cell growth. The company's active drug pipeline includes several promising candidates: Fadraciclib, a cyclin-dependent kinase (CDK) inhibitor, is presently undergoing Phase 1/2 clinical studies for solid tumors and is also being evaluated in combination with venetoclax for patients with chronic lymphocytic leukemia that has recurred or is resistant to previous therapies. CYC140, a polo-like kinase inhibitor, has progressed to Phase 1/2 clinical trials for the treatment of both advanced leukemias and solid malignancies. Sapacitabine, an innovative orally available nucleoside analog (a prodrug of CNDAC), is also in Phase 1/2 clinical trials, targeting acute myeloid leukemia and myelodysplastic syndrome. The pipeline further features Seliciclib, another CDK inhibitor, which is being investigated in investigator-sponsored trials (ISTs), including a Phase 2 study for Cushing's disease and a Phase 1/2 study for advanced rheumatoid arthritis. In a key strategic alliance, Cyclacel has collaborated with the University of Texas MD Anderson Cancer Center. This partnership aims to clinically assess the safety and therapeutic potential of three of Cyclacel's compounds in patients with a range of blood cancers, such as chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other forms of advanced leukemia. The company's main operational base is situated in Berkeley Heights, New Jersey.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 10:25 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $29.00K-3.33% vs estimate |
| Q4 2023 | Mar 19, 2024 | -$14.94-23,434.65% vs estimate | $31.00K |
|---|
| Q3 2023 | Nov 13, 2023 | -$17.62-374,844.68% vs estimate | $16.00K |
|---|
THE ANALYST VIEW
7 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
$275.20+$4.16 (+1.53%)
Johnson & Johnson’s quoted price sits in the upper half of its reported 52-week range, 2.09% below the high.
$14.20+$0.34 (+2.45%)
Korro Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 66.74% below the high.
$1.06-$0.06 (-5.36%)
Millendo Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 6.19% below the high.
$0.26-$0.01 (-3.13%)
Applied Molecular Transport Inc.’s quoted price sits in the lower half of its reported 52-week range, 68.69% below the high.
$0.10$0.00 (0.0%)
ObsEva S.A.’s quoted price sits in the lower half of its reported 52-week range, 95.24% below the high.
$0.39+$0.03 (+8.48%)
Apexigen, Inc.’s quoted price sits in the lower half of its reported 52-week range, 95.35% below the high.
$0.20-$0.00 (-1.85%)
ESSA Pharma Inc.’s quoted price sits in the lower half of its reported 52-week range, 96.88% below the high.
